Nkarta (NKTX) Return on Capital Employed (2020 - 2026)
Nkarta (NKTX) posted quarterly Return on Capital Employed of 31.44% for Q1 2026, down 318.0% year-over-year from 14.42% in Q1 2025, and down 1.4% quarter-over-quarter from 31.01% in Q4 2025.
Nkarta (NKTX) Return on Capital Employed (2020 - 2026) Analysis & Trends
Nkarta's Return on Capital Employed history runs 7 years deep, the most recent figure standing at 31.44% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 318.0% year-over-year to 31.44%; the TTM figure through Mar 2026 stood at 31.44% (down 318.0% YoY), while the FY2025 annual figure was 28.34%, up 210.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 31.44%, down from 31.01% in the prior quarter.
- The five-year high for Return on Capital Employed was 22.39% in Q3 2022, with the low at 35.67% in Q4 2023.
- The 5-year median for Return on Capital Employed is 28.93% (2023), against an average of 28.77%.
- The sharpest annual moves came in 2022 and 2024: Return on Capital Employed slumped 1421 bps in 2022, then soared 996 bps in 2024.
- Nkarta's Return on Capital Employed stood at 25.51% in 2022, then sank by 40 bps to 35.67% in 2023, then rose by 28 bps to 25.76% in 2024, then fell by 20 bps to 31.01% in 2025, then declined by 1 bps to 31.44% in 2026.
- Business Quant data shows NKTX's Return on Capital Employed at 31.44% in Q1 2026, 31.01% in Q4 2025, and 29.12% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Nkarta | 201.14 Mn | 201.14 Mn | - | -39.92% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -39.92% |
| Mar 31, 2026 | -31.44% |
| Dec 31, 2025 | -31.01% |
| Sep 30, 2025 | -29.12% |
| Jun 30, 2025 | -29.16% |
| Mar 31, 2025 | -28.26% |
| Dec 31, 2024 | -25.76% |
| Sep 30, 2024 | -24.67% |
| Jun 30, 2024 | -22.76% |
| Mar 31, 2024 | -28.55% |
| Dec 31, 2023 | -35.67% |
| Sep 30, 2023 | -34.57% |
| Jun 30, 2023 | -32.71% |
| Mar 31, 2023 | -28.93% |
| Dec 31, 2022 | -25.51% |
| Sep 30, 2022 | -22.39% |
| Jun 30, 2022 | -25.28% |
| Mar 31, 2022 | -33.32% |
| Dec 31, 2021 | -31.98% |
| Sep 30, 2021 | -28.24% |